Live Analyst Rating Changes 10175 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Michael Okunewitch
MAXI
Michael Okunewitch
Maxim Group
Wall Street Analyst
★☆☆☆☆
#2984
on 13Foresight · ranked by our own returns
34%
Success Rate
-9.9%
Average Return
14 of 41 calls profitable · -324.7% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 34% of Michael Okunewitch's ratings turned a profit when each position was held for 1 year — averaging -9.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

119 Buy 14 Hold 0 Sell
Michael's Stock Coverage 30 ratings · 2026-07-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
ATAI
Atai Beckley N.V.
 Jul 17, 2026 HOLD Strong Buy
+69.3% avg upside
17 analysts
 — -1.1%
RANI
Rani Therapeutics Holdings
 Jul 15, 2026 BUY Strong Buy
+1262.4% avg upside
10 analysts
$5.00
616.98% Upside
 +0.0%
CMMB
Chemomab Therapeutics
 Jul 13, 2026 BUY Strong Buy
+1643.6% avg upside
6 analysts
$5.00
220.52% Upside
 -7.9%
VNRX
VolitionRX
 Jul 07, 2026 BUY Strong Buy
+738.4% avg upside
11 analysts
$4.00
263.73% Upside
 -17.1%
HCWB
HCW Biologics
 Jun 24, 2026 BUY Strong Buy
+25.0% avg upside
1 analyst
$5.00
24.98% Upside
 -39.0%
DFTX
Definium Therapeutics
 Jun 23, 2026 BUY Strong Buy
-2.7% avg upside
20 analysts
$50.00
12.95% Upside
 +21.9%
KPRX
Kiora Pharmaceuticals
 Jun 22, 2026 BUY Buy
+240.3% avg upside
6 analysts
$12.00
356.33% Upside
 +3.2%
CTOR
Citius Oncology
 Jun 02, 2026 BUY Strong Buy
+480.7% avg upside
1 analyst
$4.00
480.73% Upside
 -12.9%
MDWD
Mediwound
 Jun 01, 2026 BUY Strong Buy
+47.8% avg upside
13 analysts
$30.00
105.31% Upside
 +5.7%
BLTE
Belite Bio, Inc. ADR
 May 27, 2026 BUY Strong Buy
+21.7% avg upside
10 analysts
$200.00
33.31% Upside
 +5.6%
AIDX
20/20 Biolabs, Inc.
 May 21, 2026 BUY Strong Buy
+555.2% avg upside
2 analysts
$5.00
866.03% Upside
 -56.2%
GILD
Gilead Sciences
 May 20, 2026 BUY Strong Buy
-11.2% avg upside
66 analysts
$165.00
22.96% Upside
 +3.4%
ACRV
Acrivon Therapeutics, Inc.
 May 18, 2026 BUY Strong Buy
+722.9% avg upside
13 analysts
$7.00
300.08% Upside
 ·
LCTX
Lineage Therap
 May 14, 2026 BUY Strong Buy
+377.4% avg upside
16 analysts
$3.00
158.67% Upside
 -6.9%
LGVN
Longeveron
 May 11, 2026 HOLD Strong Buy
+7188.3% avg upside
4 analysts
 — -26.9%
EVAX
Evaxion Biotech
 May 07, 2026 BUY Strong Buy
+309.7% avg upside
6 analysts
$10.00
225.11% Upside
 -23.3%
OCGN
Ocugen
 May 06, 2026 BUY Strong Buy
+580.1% avg upside
17 analysts
$8.00
488.15% Upside
 -6.9%
FBLG
FibroBiologics, Inc.
 May 04, 2026 HOLD Buy
+1097.8% avg upside
4 analysts
 — -39.1%
NGEN
NervGen Pharma
 Apr 09, 2026 BUY Strong Buy
+481.4% avg upside
9 analysts
$12.00
618.55% Upside
 -60.3%
BRTX
BioRestorative Therapies
 Apr 08, 2026 BUY Strong Buy
+2294.5% avg upside
3 analysts
$1.00
199.34% Upside
 +36.6%
CMPS
COMPASS Pathways
 Mar 26, 2026 BUY Strong Buy
+79.4% avg upside
19 analysts
$12.00
2.86% Downside
 +119.5%
RADX
Radiopharm Theranostics Limited Sponsored ADR
 Mar 25, 2026 BUY Strong Buy
+313.9% avg upside
6 analysts
$15.00
238.69% Upside
 -0.9%
QUCY
Quantum Cyber
 Mar 06, 2026 HOLD Buy
+225.1% avg upside
4 analysts
 — +43.4%
CTXR
Citius Pharmaceuticals
 Sep 23, 2025 HOLD Strong Buy
+908.5% avg upside
3 analysts
 — -55.6%
ALZN
Alzamend Neuro
 Sep 13, 2025 HOLD Buy
+1218.2% avg upside
2 analysts
$6.90
470.16% Upside
 -48.1%
ANEB
Anebulo Pharmaceuticals
 Jul 24, 2025 HOLD Strong Buy
+962.2% avg upside
5 analysts
 — -89.6%
ATHE
Alterity Therapeutics
 Mar 03, 2025 BUY Buy
+90.8% avg upside
6 analysts
$12.00
140.90% Upside
 -6.6%
LEXX
Lexaria Bioscience
 Sep 13, 2024 BUY Strong Buy
+1158.2% avg upside
3 analysts
$12.00
1786.56% Upside
 -65.3%
TSE:IWIN
Irwin Naturals Inc
 Dec 19, 2023 HOLD Buy
+2802.9% avg upside
2 analysts
 — +17.6%
CIRC
Circle8 Group
 May 09, 2023 BUY Strong Buy
+676.9% avg upside
2 analysts
 — ·
🔒 25 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Michael Okunewitch — Frequently Asked Questions
How accurate are Michael Okunewitch's stock ratings?
Based on the calls 13Foresight could measure, about 34% of Michael's ratings were profitable over a one-year hold, with an average return of -9.9% per rating, or -324.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Michael ranked on 13Foresight?
Michael Okunewitch is currently ranked #2984 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Michael cover?
Michael most recently has ratings on ATAI, RANI, CMMB, VNRX, HCWB, DFTX, KPRX, CTOR, MDWD, BLTE, AIDX, GILD and 18 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.